- HK$84.10bn
- HK$79.10bn
- CNY3.06bn
Akeso jumps as cancer drug helps patients live longer in China trial
Corrected: Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial (May 31)
J&T Global Express leads gain in newcomers to Hang Seng Index
HK-listed Akeso slides to 3-week low
Brief: Akeso FY Revenue RMB 3,056.3 Million
Brief: Akeso And Inovio Announce Clinical Collaboration To Advance Novel Combination Therapy For Glioblastoma (Gbm)
Brief: Inovio And Akeso Announce Clinical Collaboration To Advance Novel Combination Therapy For Glioblastoma (Gbm)
Brief: Akeso Granted Exclusive Commercialization Rights For Ebronucimab Injection To Jumpcan Pharmaceutical
Brief: Akeso Announces First Patient Dosed In Phase I Trial Of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab
Summit slides after not disclosing overall survival benefit in lung cancer trial
Summit falls after not disclosing overall survival benefit in lung cancer trial
Summit shares tumble on mixed data for lung cancer drug (updated)
Summit shares tumble on mixed data for lung cancer drug
Summit Therapeutics slides after mixed data for lung cancer drug
HK-listed Akeso falls on discounted share sale
Brief: Akeso Logs H1 Gross Profit RMB 1,120.7 Mln
Live Markets: Chinese biotech licensing deals draw U.S. interest despite modest size, Macquarie says
Summit slips as Leerink doubts cancer drug can match Keytruda's success
China's Akeso rises on approval for its first-line cervical cancer treatment